Update on taxane development: new analogs and new formulations.

There was also a trend for greater median survival for all patients treated with Abraxane than with paclitaxel that did not reach statistical significance (65 vs 55.7 weeks, respectively; P = 0.374); however, this difference was statistically significant in patients who received Abraxane as a second-line or greater therapy (56.4 vs 46.7 weeks, respectively; P = 0.024). 6 Recently Gradishar et al published a Phase II study in patients with previously

also in 111,027 other papers